|
Model Number CB11R31R |
Device Problem
Obstruction of Flow (2423)
|
Patient Problem
No Clinical Signs, Symptoms or Conditions (4582)
|
Event Date 02/22/2024 |
Event Type
malfunction
|
Manufacturer Narrative
|
Device evaluation summary: visual inspection of the identified bag spike port shows evidence of a deformity which would occlude a portion of the bag spike causing it to flow poorly.The bag spike was not returned for testing.Reason for return was confirmed.Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
|
Event Description
|
Medtronic received information that during use of a custom tubing pack, it was reported that when trying to transfer blood out of the collection bag to the patient, flow through the left hand side port (as you are looking at the graduations on the bag) was slow and appeared impeded.The right hand port was used without any issues of flow.This is the second case today the same incident occurred according to the perfusionist.The first case today the exact same situation happened.No issues to the patient as they were able to use the right hand side port.There was no adverse patient effect associated with this event.Medtronic received additional information that the blockage was in the left hand side port if looking at the graduations on the bag.The patient was on cardiopulmonary bypass for 1.30 hours when the blockage occurred.Crystalloid solution was used during prime.The patient had not previously been on heparin or other anti- coagulant therapy.Anti- coagulation was assessed using the actplus instrument.
|
|
Manufacturer Narrative
|
Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
|
Search Alerts/Recalls
|
|
|